INMODE LTD.
INMD
|
$17.42
0.46%
0.46%
1.7M
|
Health Technology
(0.0% 1d) (-18.0% 1m) (-53.5% 1y) (0.0% 2d) (-0.2% 3d) (-1.6% 7d) (104.03% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 1,462,974,488
http://www.inmodemd.com
Sec Filling | Patents | 251 employees
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.
skin israel aesthetic treatment
add to watch list Paper trade email alert is off
Aclaris Therapeutics, Inc.
ACRS
|
$1.25
1.63%
1.6%
580K
|
Health Technology
(0.0% 1d) (3.3% 1m) (-86.4% 1y) (0.8% 2d) (0.8% 3d) (2.5% 7d) (-10.23% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 88,656,303
http://www.aclaristx.com
Sec Filling | Patents | 77 employees
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
immunology rheumatoid arthritis aesthetic msa
Drugs
Rhofade (oxymetazoline Hydrochloride)add to watch list Paper trade email alert is off
Align Technology, Inc.
ALGN
|
$298.99
-0.78%
-0.79%
520K
|
Health Technology
(0.0% 1d) (-6.9% 1m) (-15.8% 1y) (0.0% 2d) (0.0% 3d) (-1.9% 7d) (3.5% volume)
Earnings Calendar: 2024-01-31
Market Cap: $ 22,499,733,613
http://www.aligntech.com
Sec Filling | Patents | 14530 employees
(US) Align Technology, Inc. engages in the design, manufacture, and market of orthodontics, restorative, and aesthetic dentistry products. It operates through the Clear Aligner, and Scanner and Services segments. The Clear Aligner segment consists of invisalign full, teen, and assist products, and vivera retainers for treating malocclusion. The Scanner and Services segment comprises of intraoral scanning systems such as single hardware platforms and restorative or orthodontic software options, ancillary products, and other related additional services. The company was founded by Zia Chishti, Brian Freyburger and Kelsey Wirth in March 1997 and is headquartered in San Jose, CA.
aesthetic
add to watch list Paper trade email alert is off
Evolus, Inc.
EOLS
|
$11.49
-0.61%
-0.61%
350K
|
Health Technology
(0.0% 1d) (-16.4% 1m) (26.0% 1y) (0.0% 2d) (-2.9% 3d) (-3.0% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 665,772,217
http://www.evolus.com
Sec Filling | Patents | 235 employees
(United States) Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.
aesthetic brands treatment
Drugs
Jeuveau (Prabotulinum Toxin Type A)add to watch list Paper trade email alert is off
Cara Therapeutics, Inc.
CARA
|
$0.6816
-1.22%
-1.23%
350K
|
Health Technology
(0.0% 1d) (-26.0% 1m) (-83.9% 1y) (-4.3% 2d) (-4.3% 3d) (-7.0% 7d) (-3.11% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 37,253,811
http://www.caratherapeutics.com
Sec Filling | Patents | 67 employees
(US) CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
opioid analgesic aesthetic
add to watch list Paper trade email alert is off
Histogen Inc.
HSTO
1
d
|
$0.5
67.46%
530
|
Health Technology
(0.0% 1d) (25.0% 1m) (-48.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-68.82% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 2,135,880
http://www.histogen.com
Sec Filling | Patents | 6 employees
Histogen, Inc. engages in the development of patented, innovative technologies that replace and regenerate tissues in the body for the aesthetic and therapeutic markets. Its technology is based on the discovery that growing fibroblast cells under simulated embryonic conditions induces them to become multipotent stem cells. The environment created by its proprietary process mimics the conditions within the womb very low oxygen and suspension. When cultured under these conditions, the induced multipotent stem cells generate biological materials that stimulate a patient’s own stem cells to activate and regenerate tissue. This results in potential therapeutic benefits in multiple treatment settings, including skin care, orthopedic indications such as cartilage formation and spinal disc repair, wound healing and dermal fillers. The company was founded on July 13, 2005 by Steven J. Mento and is headquartered in San Diego, CA.
dermatitis cartilage skin stem cell t-cell aesthetic treatment ceiling
add to watch list Paper trade email alert is off
Citius Pharmaceuticals, Inc.
CTXR
|
$0.7477
-7.18%
-7.73%
1.7M
|
Health Technology
(0.0% 1d) (-0.0% 1m) (-51.0% 1y) (0.0% 2d) (0.0% 3d) (-2.0% 7d) (246.97% volume)
Earnings Calendar: 2023-12-21
Market Cap: $ 118,955,168
http://www.citiuspharma.com
Sec Filling | Patents | 9 employees
(US) Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. It is currently advancing three proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; CITI-002, which provides anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and CITI-101, which is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
cancer education antibiotics aesthetic hemorrhoids bloodstream ontak injection
add to watch list Paper trade email alert is off
CollPlant Biotechnologies Ltd.
CLGN
|
$5.22
-2.54%
1.2K
|
Health Technology
(0.0% 1d) (3.6% 1m) (-28.9% 1y) (0.0% 2d) (0.0% 3d) (0.5% 7d) (-72.07% volume)
Earnings Calendar: 2024-03-29
Market Cap: $ 59,782,948
http://www.collplant.com
Sec Filling | Patents | 46 employees
(IL) CollPlant Biotechnologies Ltd. is a regenerative medicine company, which engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. The company's products include VergenixSTR, VergenixFG, and CollPlant Surgical Matrix. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.
israel aesthetic
add to watch list Paper trade email alert is off
Cutera, Inc.
CUTR
|
$1.95
-15.22%
-17.95%
1.1M
|
Health Technology
(0.0% 1d) (-15.2% 1m) (-91.3% 1y) (0.0% 2d) (0.0% 3d) (-11.8% 7d) (13.32% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 38,890,556
http://www.cutera.com
Sec Filling | Patents | 447 employees
(US) Cutera, Inc. sells aesthetic medical equipment and services, and distributes skincare products, to medical practitioners. The firm designs, develops, manufactures, distributes and markets light and energy-based product platforms for use by physicians and other practitioners, enabling them to offer safe and effective aesthetic treatments to customers. Its products include enlighten, excel HR, excel V, excel V+, Juliet, Secret RF, truSculpt flex, truSculpt iD, truSculpt 3D and xeo. The company was founded by David A. Gollnick in August 1998 and is headquartered in Brisbane, CA.
energy aesthetic treatment 3d
add to watch list Paper trade email alert is off
Venus Concept Inc.
VERO
|
$0.85
1.19%
1.18%
15K
|
Health Technology
(0.0% 1d) (25.6% 1m) (-73.3% 1y) (0.0% 2d) (5.2% 3d) (32.8% 7d) (-72.1% volume)
Earnings Calendar: 2024-04-01
Market Cap: $ 5,401,946
http://www.venusconcept.com
Sec Filling | Patents | 525 employees
(CA) Venus Concept, Inc. develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related practice enhancement services. Its product portfolio consists of aesthetic device platforms which includes venus versa, venus legacy, venus velocity, venus fiore, venus viva, venus freeze plus, and venus bliss. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.
aesthetic
add to watch list Paper trade email alert is off
Revance Therapeutics, Inc.
RVNC
|
$3.77
-0.53%
-0.53%
1.6M
|
Health Technology
(0.0% 1d) (-27.2% 1m) (-88.2% 1y) (0.0% 2d) (0.5% 3d) (-4.8% 7d) (-5.32% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 392,892,865
http://www.revance.com
Sec Filling | Patents | 193 employees
(United States) Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
aesthetic
add to watch list Paper trade email alert is off
Sientra, Inc.
SIEN
|
$0.174
0.69%
3.4M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-86.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-96.6% volume)
Earnings Calendar: 2023-11-14
Market Cap: $ 2,080,642
http://www.sientra.com
Sec Filling | Patents | 339 employees
(United States) Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device which uses consumable single-use bioTips. The company was founded by Hani M. Zeini on August 29, 2003 and is headquartered in Santa Barbara, CA.
aesthetic brands msa
Drugs
BIOCORNEUM ADVANCED SCAR TREATMENT ANTI-ITCH (Hydrocortisone acetate 1%)BIOCORNEUM PLUS SPF 30 ADVANCED SCAR TREATMENT (Octinoxate Octisalate Octocrylene Oxybenzone)
add to watch list Paper trade email alert is off
Bausch Health Companies Inc.
BHC
|
$8.69
1.05%
0.0%
2.9M
|
Health Technology
(0.0% 1d) (-8.5% 1m) (12.9% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (0.83% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 3,137,000,875
http://www.bauschhealth.com
Sec Filling | Patents | 21700 employees
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.
glass urea aesthetic women brands neurological
add to watch list Paper trade email alert is off
Baxter International Inc.
BAX
|
$39.47
-0.45%
0.0%
2.8M
|
Health Technology
(0.0% 1d) (-6.0% 1m) (-12.9% 1y) (0.0% 2d) (-0.6% 3d) (-1.4% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-08
Market Cap: $ 20,043,948,938
http://www.baxter.com
Sec Filling | Patents | 50000 employees
(US) Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
nutrition renal aesthetic injection
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10